Trial Profile
Brivanib (BMS-582664, Brivanib Alaninate) in Treatment of Refractory Metastatic Renal Cell Carcinoma - A Phase II Pharmacodynamic and Baseline Biomarker Study
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Brivanib alaninate (Primary) ; Girentuximab I-124 (Primary)
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- 18 Mar 2021 Status changed from suspended to discontinued.
- 01 Dec 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 13 Dec 2010 New trial record